{Reference Type}: Journal Article
{Title}: Association of Helicobacter pylori treatment with Parkinsonism and related disorders: A systematic review and meta-analysis.
{Author}: Bai F;Li X;
{Journal}: Life Sci
{Volume}: 281
{Issue}: 0
{Year}: Sep 2021 15
{Factor}: 6.78
{DOI}: 10.1016/j.lfs.2021.119767
{Abstract}: <B>OBJECTIVE: </B>Previous studies have suggested that Helicobacter pylori (H. pylori) infections may be the cause of or worsen Parkinson's disease symptoms. In this meta-analysis, all relevant studies were reviewed to assess whether H. pylori treatment would benefit patients with Parkinson's disease.<BR><B>METHODS: </B>Systemically searches were carried out in MEDLINE and other popular databases. The software RevMan 5.2 was used for meta-analysis. The mean difference (MD) was used as the effect size to draw forest plots.<BR><B>RESULTS: </B>A total of 10 qualified studies were included. For bradykinesia, the pooled MD value of stride length was -75.76, 95% CI [-109.37, -42.15, P < 0.05]; for myotonia, the pooled MD value of torque to flex was 75.24, 95% CI [27.36, 123.13, P < 0.05]. The pooled MD value of Unified Parkinson's Disease Rating Scale (UPDRS)-III scores before and after treatment was 6.27, 95% CI [1.30, 11.24, P < 0.05], suggesting that UPDRS-III scores improved in response to H. pylori treatment. The pooled MD value of levodopa onset time (min) was 14.91, 95% CI [8.92, 20.90, P < 0.05].<BR><B>CONCLUSIONS: </B>H. pylori treatment may improve the stride length in the bradykinesia index and significantly improve UPDRS-III scores.